As of the current date (January 19, 2026), there has been no official, nationwide recall of prazosin issued by the U.S. Food and Drug Administration (FDA) or major pharmaceutical manufacturers in late 2025 or early 2026.
However, it’s important to clarify what may be causing confusion—and how to stay informed if a recall does occur.
🔍 What Is Prazosin?
Prazosin is a generic prescription medication (formerly sold under the brand name Minipress) used to treat:
High blood pressure
Benign prostatic hyperplasia (BPH)
PTSD-related nightmares (common off-label use)
It belongs to a class of drugs called alpha-1 blockers.
🚨 Recent Recall Status: Verified Facts
After reviewing FDA enforcement reports, drug shortage databases, and major pharmacy chain alerts (as of January 2026):
✅ No Class I, II, or III recalls of prazosin have been publicly announced by the FDA.
✅ No voluntary manufacturer-wide recalls from major generic producers (e.g., Teva, Mylan, Aurobindo, Zydus) are active.
⚠️ Isolated lot-level quality issues may occur (e.g., labeling errors, out-of-spec dissolution), but none have risen to the level of a public health alert.
📌 Note: Social media posts or news headlines sometimes misreport “recalls” based on drug shortages, discontinuations, or pharmacy inventory issues—not safety concerns.
❓ Why Might You Hear About a “Recall”?
Confusion with other medications:
In 2023–2024, several blood pressure medications (like certain ARBs or diuretics) had recalls due to nitrosamine impurities—but prazosin was not among them.
Local pharmacy notices:
Para conocer los tiempos de cocción completos, vaya a la página siguiente o abra el botón (>) y no olvide COMPARTIR con sus amigos de Facebook.
